ASH Clinical News May 2017 NEW | Page 50

Features Agent Orange and Hematologic Malignancies The Fog of War Still Hovers M ore than 40 years after the Vietnam War, the fog of Agent Orange hangs thick over veterans and those providing their medical care. Aging veterans suf- fer from an extensive list of diseases, including several hematologic malig- nancies, deemed related, or possibly related, to exposure to Agent Orange. The number of affected veterans will likely increase as new conditions are added to the official list of “pre- sumptive diseases” and as controver- sies are resolved regarding which vet- erans were affected (and how the U.S. government should compensate and care for them). Although the science connecting Agent Orange exposure and certain hematologic malignancies is sound, the story of Agent Orange is far from clear-cut. It is covered with a sticky mist of politics, controversy, blame, and denial. 48 ASH Clinical News “Many cases we see in our clinics may resonate back to historic events that we don’t pay much attention to, in part because it is difficult to dissect the details,” said C. Ola Landgren, MD, PhD, chief of the myeloma service at Memorial Sloan Kettering Cancer Center in New York, who has extensively studied the link between environmental exposures and multiple myeloma (MM). To help unravel the story, ASH Clinical News spoke with Dr. Landgren and ASH Clinical News Associate Editor David Steensma, MD, about the science behind Agent Orange, the clinical considerations of exposure, and the task of caring for ill veterans. Making “The List” The U.S. military sprayed Agent Or- ange in military operations from 1962 to 1971. In 1969, it became widely known that the 2,4,5-T component of Agent Orange was inadvertently contaminated with the potent dioxin TCDD. (See SIDEBAR on page 50 for a history of Agent Orange and its uses.) In response to a growing body of evidence linking dioxin toxicity to adverse health effects and birth out- comes in returning service members and Vietnamese citizens, the military stopped spraying Agent Orange in January 1971. In 1991, Congress passed the Agent Orange Act, giving the U.S. Department of Veterans Affairs (VA) the authority to declare certain condi- tions “presumptive” to exposure to Agent Orange/dioxin and to compen- sate affected veterans for treatment. Qualifying servicemen and women, their spouses, and their biological chil- dren with these conditions are eligible to receive compensation, health care, and vocational training from the VA. The list of conditions includes ischemic heart disease, type 2 diabe- tes, and a variety of hematologic and other malignancies ( FIGURE ). The VA also presumes that certain birth de- fects, namely spina bifida, in children of Vietnam and Korean War veterans are associated with veterans’ qualify- ing military service. Even decades later, though, the list of covered condi- tions remains in flux. To address continuing uncertainty about the long-term health effects of Agent Orange in veterans, the 1991 Agent Orange Act also mandated that the National Academy of Medicine (NAM; formerly known as the Institute of Medicine) perform periodic, comprehensive reviews of scientific and clinical information regarding the health effects of exposure to sprayed herbicides. May 2017